Recent Mayo Clinic-led observational study, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, has revealed promising insights into obesity management for postmenopausal women. The research analyzed data from 120 adults with overweight or obesity treated with tirzepatide—a GLP-1 receptor agonist approved by the US FDA for weight management and type 2 diabetes—for at least 12 months. Notably, postmenopausal women concurrently using menopausal hormone therapy (MHT) experienced approximately 35% greater weight loss compared to those on tirzepatide alone. This finding is particularly relevant for Indian doctors, as menopause-related weight gain affects a significant proportion of women in India, where rising obesity rates contribute to cardiometabolic comorbidities. Menopause often leads to estrogen decline, promoting visceral fat accumulation and elevating risks for cardiovascular disease and type 2 diabetes. The study suggests that MHT, which is the gold standard for alleviating vasomotor symptoms like hot flashes affecting up to 75% of postmenopausal women, may synergize with tirzepatide’s appetite-suppressing effects. Preclinical evidence supports this, indicating estrogen could enhance GLP-1 pathways, potentially improving adherence to lifestyle interventions through better sleep and quality of life. Lead author Regina Castaneda, M.D., emphasized the need for personalized strategies to mitigate cardiometabolic risks in this demographic, highlighting the study’s observational nature and the possibility that healthier behaviors among MHT users influenced outcomes.

While the results are clinically meaningful, senior author Maria Daniela Hurtado Andrade, M.D., Ph.D., cautioned that causation cannot be inferred without randomized trials, as factors like symptom relief might indirectly support weight loss. This opens avenues for Indian endocrinologists and gynecologists to consider integrated approaches, especially in a context where cultural and socioeconomic factors influence menopause management. Future research, funded by the Mayo Clinic Center for Women’s Health Research, aims to validate these observations through controlled trials, exploring broader benefits on cardiometabolic markers. Such advancements could inform evidence-based protocols, potentially reducing obesity-related burdens in India’s aging female population and accelerating adoption of combined therapies. Indian specialists should monitor emerging data, weighing MHT’s benefits against risks like thromboembolism, and tailor treatments based on individual profiles.